Keyphrases
Colesevelam
100%
Type 2 Diabetes Prevention
100%
Glucose-lowering Drugs
42%
Hemoglobin A1c (HbA1c)
42%
Type 2 Diabetes Mellitus (T2DM)
28%
Low-density Lipoprotein
28%
Clinical Efficacy
28%
Lipids
14%
Type 2 Diabetic Patients
14%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Statins
14%
HbA1c Reduction
14%
Market Authorization
14%
Renal Impairment
14%
Treatment Goals
14%
Renal Transplant Recipients
14%
Dyslipidemia
14%
Expert Opinion
14%
Hyperglycemia
14%
Patient Selection
14%
Antidiabetic Agents
14%
Placebo
14%
Phase III Clinical Trial
14%
Intervention Strategies
14%
Cholesterol
14%
Clinical Safety
14%
Four-phase
14%
Cardiovascular Mortality
14%
Clinically Significant
14%
Pharmacokinetics-pharmacodynamics (PK-PD)
14%
Global Health Issue
14%
Area Cover
14%
Multiple Risk Factors
14%
Monotherapy
14%
Clinical Potential
14%
Safety Data
14%
Efficacy Data
14%
Hypertension
14%
Tolerability
14%
Add-on Treatment
14%
Cardiovascular Risk
14%
Cardiovascular Morbidity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Colesevelam
100%
Non Insulin Dependent Diabetes Mellitus
100%
Hemoglobin A1c
57%
Low Density Lipoprotein
28%
Low Density Lipoprotein Cholesterol
14%
Statin (Protein)
14%
Antidiabetic Agent
14%
Placebo
14%
Cardiovascular Disease
14%
Tolerability
14%
Pharmacokinetic
14%
Clinical Trial
14%
Monotherapy
14%
Dyslipidemia
14%
Hyperglycemia
14%
Pharmacodynamics
14%